Checkpoint Inhibitors as First-line Treatments for Lung Cancer: What You Need to Know

1.00 CME
$0 FEE
Checkpoint Inhibitors as First-line Treatments for Lung Cancer: What You Need to Know


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Activity Description

Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020 within the United States, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease. More than half of patients die within 1 year of diagnosis, and 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this educational activity, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.

Target Audience

The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants, and other health care professionals involved in the management of patients with lung cancer.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Compare available checkpoint inhibitor-based approaches for the management of patients with advanced NSCLC in order to guide individualization of first-line treatment.
  • Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with SCLC, including those with extensive disease.


Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Research Program
Vanderbilt Ingram Cancer Center
Nashville, TN

Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.00 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, June 30, 2020, through June 29, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Faculty reports the following relationship(s)

Leora Horn, MD, MSc, FRCPC
Consulting Fee: Amgen, AstraZeneca, Bayer, EMD Serono, Genentech-Roche, Incyte, Merck, Pfizer

Mark A. Socinski, MD
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Speakers Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Contracted Research: AstraZeneca, Genentech, Novartis, Spectrum

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at